Feb 25, 2009 by Brian Orelli, PhDPfizer Doesn't Like RerunsThe company drops two drugs that had made it as far as phase 3 trials.
Feb 25, 2009 by Brian Orelli, PhDThe Best Kind of Generic GrowthPharmacy benefit managers profit from penny-pinchers.
Feb 24, 2009 by Brian Orelli, PhDPfizer: Diversified Dreams, Dubious DecisionsThe drugmaker wants to become the next J&J. Nice thought, but…
Feb 23, 2009 by Brian Orelli, PhDWhy Do You Hate Health-Care Companies So Much? What the Supreme Court giveth, Congress can taketh away.
Feb 23, 2009 by Brian Orelli, PhDThe DOJ v. Johnson & Johnson The Department of Justice isn't so happy these days with the health-care giant.
Feb 23, 2009 by Brian Orelli, PhDGenzyme Playing DefenseThe latest good news from this company won't help the top line much.
Feb 20, 2009 by Brian Orelli, PhDThe Skinny on Diabetes DrugsThis drug class has a great side effect.
Feb 20, 2009 by Brian Orelli, PhDGeneric Synergies, Stellar Earnings GrowthMylan is working through its growing pains.
Feb 20, 2009 by Brian Orelli, PhDThe Stimulus Bill Could Bite These CompaniesThis isn't the kind of stimulus the companies need.
Feb 19, 2009 by Brian Orelli, PhDBioMarin Is Off TrackThe drugmaker is predicting it will swing to a loss for the year.
Feb 13, 2009 by Brian Orelli, PhDThe Easy Way to Develop DrugsMerck buys a pipeline of follow-on biologics and a building to produce them.
Feb 12, 2009 by Brian Orelli, PhDStimulus Could Be Bitter Pill for Some InvestorsHealth-care shareholders need to watch provisions of the bill closely.
Feb 12, 2009 by Brian Orelli, PhDPatent Cliff? Bring It OnSanofi-aventis isn't interested in doing a large deal.
